ESMO: European Society for Medical Oncology

1. Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma

   Findings from a substudy 02C of the KEYMAKER-U02 trial

2. Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

   Findings from the RedirecTT-1 study

3. FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

   Evidence for efficacy is based on the results from the ADRIATIC study

4. EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan

   It is intended for the treatment of patients with advanced clear cell renal cell carcinoma and von Hippel-Lindau disease-associated tumours

5. Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE

   Findings from the EMERALD-1 and LEAP-012 studies